Cargando…

Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole

BACKGROUND: Urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria are increasing worldwide. At our hospital, the number of pediatric patients hospitalized because of an upper urinary tract infection has dramatically increased since 2016. In total, 60.5% of urinary tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Horie, Akiyoshi, Nariai, Akiyoshi, Katou, Fumihide, Abe, Yasuhiro, Saito, Yuya, Koike, Daisuke, Hirade, Tomohiro, Ito, Tomoko, Wakuri, Miho, Fukuma, Aiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797641/
https://www.ncbi.nlm.nih.gov/pubmed/31428892
http://dx.doi.org/10.1007/s10157-019-01775-w
_version_ 1783459874512830464
author Horie, Akiyoshi
Nariai, Akiyoshi
Katou, Fumihide
Abe, Yasuhiro
Saito, Yuya
Koike, Daisuke
Hirade, Tomohiro
Ito, Tomoko
Wakuri, Miho
Fukuma, Aiko
author_facet Horie, Akiyoshi
Nariai, Akiyoshi
Katou, Fumihide
Abe, Yasuhiro
Saito, Yuya
Koike, Daisuke
Hirade, Tomohiro
Ito, Tomoko
Wakuri, Miho
Fukuma, Aiko
author_sort Horie, Akiyoshi
collection PubMed
description BACKGROUND: Urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria are increasing worldwide. At our hospital, the number of pediatric patients hospitalized because of an upper urinary tract infection has dramatically increased since 2016. In total, 60.5% of urinary tract infections are caused by extended-spectrum beta-lactamase-producing Escherichia coli. Such a high prevalence of extended-spectrum beta-lactamase-producing E. coli has not been detected previously in Japan. Therefore, we evaluated the clinical and bacteriologic characteristics and efficacy of antibiotics against upper urinary tract infections caused by E. coli in children. METHODS: This retrospective study surveyed 152 patients who were hospitalized in the pediatric department of Shimane Prefectural Central Hospital because of upper urinary tract infections caused by E. coli. Medical records were reviewed to examine patient characteristics. O antigens, antibiotic susceptibility, gene typing, and pulse-field gel electrophoresis were studied at the Shimane Prefectural Institute of Public Health and Environmental Science. RESULTS: Urine sample analyses showed extended-spectrum beta-lactamase types such as CTX-M-9 and plural virulence genes. We changed the primary antibiotic treatment to flomoxef or cefmetazole to treat upper urinary tract infections caused by Gram-negative bacilli. After changing treatment, the time to fever alleviation was significantly shortened. CONCLUSION: Extended-spectrum beta-lactamase-producing E. coli should be suspected in community-acquired upper urinary tract infections. Therefore, when treating patients, it is necessary to focus on antibiotic susceptibility and the prevalence of extended-spectrum beta-lactamase-producing bacteria found in each area. Flomoxef and cefmetazole are useful primary treatments for upper urinary tract infections caused by extended-spectrum beta-lactamase-producing E. coli.
format Online
Article
Text
id pubmed-6797641
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-67976412019-11-01 Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole Horie, Akiyoshi Nariai, Akiyoshi Katou, Fumihide Abe, Yasuhiro Saito, Yuya Koike, Daisuke Hirade, Tomohiro Ito, Tomoko Wakuri, Miho Fukuma, Aiko Clin Exp Nephrol Original Article BACKGROUND: Urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria are increasing worldwide. At our hospital, the number of pediatric patients hospitalized because of an upper urinary tract infection has dramatically increased since 2016. In total, 60.5% of urinary tract infections are caused by extended-spectrum beta-lactamase-producing Escherichia coli. Such a high prevalence of extended-spectrum beta-lactamase-producing E. coli has not been detected previously in Japan. Therefore, we evaluated the clinical and bacteriologic characteristics and efficacy of antibiotics against upper urinary tract infections caused by E. coli in children. METHODS: This retrospective study surveyed 152 patients who were hospitalized in the pediatric department of Shimane Prefectural Central Hospital because of upper urinary tract infections caused by E. coli. Medical records were reviewed to examine patient characteristics. O antigens, antibiotic susceptibility, gene typing, and pulse-field gel electrophoresis were studied at the Shimane Prefectural Institute of Public Health and Environmental Science. RESULTS: Urine sample analyses showed extended-spectrum beta-lactamase types such as CTX-M-9 and plural virulence genes. We changed the primary antibiotic treatment to flomoxef or cefmetazole to treat upper urinary tract infections caused by Gram-negative bacilli. After changing treatment, the time to fever alleviation was significantly shortened. CONCLUSION: Extended-spectrum beta-lactamase-producing E. coli should be suspected in community-acquired upper urinary tract infections. Therefore, when treating patients, it is necessary to focus on antibiotic susceptibility and the prevalence of extended-spectrum beta-lactamase-producing bacteria found in each area. Flomoxef and cefmetazole are useful primary treatments for upper urinary tract infections caused by extended-spectrum beta-lactamase-producing E. coli. Springer Singapore 2019-08-19 2019 /pmc/articles/PMC6797641/ /pubmed/31428892 http://dx.doi.org/10.1007/s10157-019-01775-w Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Horie, Akiyoshi
Nariai, Akiyoshi
Katou, Fumihide
Abe, Yasuhiro
Saito, Yuya
Koike, Daisuke
Hirade, Tomohiro
Ito, Tomoko
Wakuri, Miho
Fukuma, Aiko
Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole
title Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole
title_full Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole
title_fullStr Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole
title_full_unstemmed Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole
title_short Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole
title_sort increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing escherichia coli in children and the efficacy of flomoxef and cefmetazole
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797641/
https://www.ncbi.nlm.nih.gov/pubmed/31428892
http://dx.doi.org/10.1007/s10157-019-01775-w
work_keys_str_mv AT horieakiyoshi increasedcommunityacquiredupperurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingescherichiacoliinchildrenandtheefficacyofflomoxefandcefmetazole
AT nariaiakiyoshi increasedcommunityacquiredupperurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingescherichiacoliinchildrenandtheefficacyofflomoxefandcefmetazole
AT katoufumihide increasedcommunityacquiredupperurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingescherichiacoliinchildrenandtheefficacyofflomoxefandcefmetazole
AT abeyasuhiro increasedcommunityacquiredupperurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingescherichiacoliinchildrenandtheefficacyofflomoxefandcefmetazole
AT saitoyuya increasedcommunityacquiredupperurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingescherichiacoliinchildrenandtheefficacyofflomoxefandcefmetazole
AT koikedaisuke increasedcommunityacquiredupperurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingescherichiacoliinchildrenandtheefficacyofflomoxefandcefmetazole
AT hiradetomohiro increasedcommunityacquiredupperurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingescherichiacoliinchildrenandtheefficacyofflomoxefandcefmetazole
AT itotomoko increasedcommunityacquiredupperurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingescherichiacoliinchildrenandtheefficacyofflomoxefandcefmetazole
AT wakurimiho increasedcommunityacquiredupperurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingescherichiacoliinchildrenandtheefficacyofflomoxefandcefmetazole
AT fukumaaiko increasedcommunityacquiredupperurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingescherichiacoliinchildrenandtheefficacyofflomoxefandcefmetazole